Abstract

Despite studying the various molecular mechanisms of hepatocellular carcinoma (HCC), effective drugs and biomarkers in HCC therapy are still scarce. The present study was designed to investigate dysregulated pathways, novel biomarkers and therapeutic targets for HCC. The gene expression dataset of GSE14520, which included 362 tumor and their paired non-tumor tissues of HCC, was extracted for processing by the Robust multi-array average (RMA) algorithm in the R environment. SAM methods were leveraged to identify differentially expressed genes (DEGs). Functional analysis of DEGs was performed using DAVID. The GeneMania and Cytohubba were used to construct the PPI network. To avoid individual bias, GSEA and survival analysis were employed to verify the results. The results of these analyses indicated that separation of sister chromatids was the most aberrant phase in the progression of HCC, and the most frequently involved genes, EZH2, GINS1, TPX2, CENPF, and BUB1B, require further study to be used as drug targets or biomarkers in diagnosis and treatment of HCC.

Highlights

  • Hepatocellular carcinoma (HCC) is the third-leading cause of cancer-related deaths worldwide and its incidence continues to rise (Mittal and El-Serag, 2013)

  • Five most significantly hub genes, EZH2, GINS1, TPX2, CENPF, and BUB1B, were successfully validated by qPCR in 30 paired human HCC tissues which have no difference with the analysis results of gene expression profiling (Figure 7)

  • IHC was employed to validate the results from bioinformation analysis, which revealed the strong expression of five hub genes in HCC vs. the control group

Read more

Summary

Introduction

Hepatocellular carcinoma (HCC) is the third-leading cause of cancer-related deaths worldwide and its incidence continues to rise (Mittal and El-Serag, 2013). It mainly arise from hepatitis B virus (HBV) or hepatitis C virus (HCV) infections, and patients with cirrhosis have more opportunities to get HCC (El-Serag, 2002; Umemura et al, 2009). The limited knowledge on the molecular mechanisms of HCC contribute to poor prognosis and ineffective therapy, which leaves liver transplantation as the best choice of management (Ho et al, 2015; Turato et al, 2017).

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call